Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
← catalyst calendarSponsored by Arbutus Biopharma Corporation (industry) · ABUS — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
43actual
Sites
17
Countries
Australia, Hong Kong, Moldova +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-29 | actual | When the study began enrolling |
| Primary completion | 2025-03-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-21 | actual | The whole study's end, after follow-up |
| First posted | 2021-07-28 | actual | When this record first appeared on the registry |
| Results posted | 2026-04-29 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Hepatitis b
Interventions
- Drug: AB-729
- Drug: Peg-IFNα-2a — also filed as pegylated interferon alpha 2a
Primary outcome
what the primary-completion date above is the date OFThe Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2a
measured Up to 124 weeks
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-06-17 · 18.6 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-07-23 · 851 KB · SAP_001.pdf
Permalink · ABUS's whole pipeline · Catalyst calendar · Every registered study · What changed